Gp1815

#29

#2½

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Dale E. Yelton, et al.	Examiner:	Not Assigned
Serial No.:	08/905,293	Group Art Unit:	1815
Filed:	August 1, 1997	Docket:	30436.43USU1

Title: METHOD FOR INHIBITING IMMUNOGLOBULIN-INDUCED TOXICITY RESULTING FROM THE USE OF IMMUNOGLOBULINS IN THERAPY AND IN VIVO DIAGNOSIS

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on January 29, 1998.

By: _____
Sherlin Taghoubzadeh

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

☒ Transmittal Sheet in duplicate containing Certificate of Mailing
☒ Other: Information Disclosure Statement, Form PTO-1449 and copies of 12 references
☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2724. A duplicate of this sheet is enclosed.

MERCHANT, GOULD, SMITH, EDELL,
WELTER & SCHMIDT
Westwood Gateway II, Suite 400
11150 Santa Monica Blvd.
Los Angeles, CA 90025
(310) 445-1140

By: _____
Name: Karen S. Canady
Reg. No.: 39,927
KSC/WJW/sy

Dkt. 30436.43USU1/KSC/WJW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Dale E. Yelton and Mae Joanne Rosok	
Serial No.	:	08/905,293	Examiner : Not Assigned
Filed	:	August 1, 1997	Group Art Unit: 1815
For	:	METHOD FOR INHIBITING IMMUNOGLOBULIN-INDUCED TOXICITY RESULTING FROM THE USE OF IMMUNOGLOBULINS IN THERAPY AND IN VIVO DIAGNOSIS	

11150 Santa Monica Boulevard
Los Angeles, California 90025
January 29, 1998

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(a)

With regard to the above-identified application, applicants are aware of the art listed in the enclosed PTO Form 1449. Applicants call these references to the attention of the Examiner to satisfy disclosure requirements. The enclosed references are indicated as Exhibits 1-12 in the PTO Form 1449.

FOREIGN PATENT DOCUMENTS

European Patent Application, EP 0 699 756 A1, published March 3, 1996 (Exhibit 1)

PCT Application No. WO 94/29351, published December 22, 1994 (Exhibit 2)

OTHER DOCUMENTS

D. Yelton, et al., "Mutant Monoclonal Antibodies With Alterations in Biological Functions," J. Exp. Medicine, Vol. 56, pp. 1131-1148, October 1982 (Exhibit 3)

Mueller, et al., "Serum Half-Life and Tumor Localization of a Chimeric Antibody Deleted of the C_H2 Domain and Directed Against the Disialoganglioside GD2," P.N.A.S., Vol. 87, pp. 5702-5705, August 1990 (Exhibit 4)

H. Garrigues, et al., "Detection of a Human Melanoma-Associated Antigen, p97, in Histological Sections of Primary Human Melanomas, Int. J. Cancer, Vol. 29, pp. 511-515, 1982 (Exhibit 5)

Alexander R. Duncan, et al., "The Binding Site for Clq on IgG" Nature, Vol. 332, pp. 738-740, April 1988 (Exhibit 6)

Mi-Hua Tao, et al., "Structural Features of Human Immunoglobulin G That Determine Isotype-Specific Differences in Complement Activation" J. Exp. Med., Vol. 178, No. 2, pp. 661-667, August 1993 (Exhibit 7)

Yuanyuan. Xu, et al., "Residue at Position 331 in the IgG1 and IgG4 Domains Contributes to Their Differential Ability to Bind and Activate Complement" J. Biol. Chem., Vol. 269, No. 5, pp. 3469-3474, February 1994 (Exhibit 8)

A. Morgan, et al., "The N-Terminal End of the C_H2 Domain of Chimeric Human IgG1 Anti-HLA-DR is Necessary for Clq, FcγRI and FcγRIII Binding" Immunology, Vol. 86, pp. 319-324, 1995 (Exhibit 9)

Mae Joanne Rosok, et al. "A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab," J. Biol. Chem., Vol. 271, No. 37, pp. 22611-22618, September 1996 (Exhibit 10)

Mi-Hua Tao, et al., "The Differential Ability of Human IgG1 and IgG4 to Activate Complement is Determined by the COOH-Terminal Sequence of the C_H2 Domain," J. Exp. Med., Vol. 173, pp. 1025-1028, April 1991 (Exhibit 11)

I. Hellström, et al., "Strong Antitumor Activities of IgG3 Antibodies to a Human Melanoma-Associated Ganglioside," P.N.A.S., Vol. 82, pp. 1499-1502, March 1985 (Exhibit 12)

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed PTO Form 1449 (modified).

Applicants hereby fulfill their duty of disclosure. It is believed that the instant application includes claims patentably distinct from the disclosures in the cited prior art, and consideration and allowance of the claims is requested.

Should any fee be deemed due in connection with this filing, applicants authorize the Patent Office to charge Deposit Account No. 13-2724.

Respectfully submitted,



Karen S. Canady
Registration No. 39,927
Attorney for Applicants
Merchant & Gould
Suite 400
11150 Santa Monica Blvd.
Los Angeles, CA 90025
(310) 445-1140

I hereby certify that this paper is being deposited this date with the U.S. Postal Service by first class mail addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature Date 1/29/98